Filtered By:
Specialty: Drugs & Pharmacology
Drug: Temodar
This page shows you your search results in order of date.
Order by Relevance | Date
Total 107 results found since Jan 2013.
Quality by design engineered, enhanced anticancer activity of temozolomide and resveratrol coloaded NLC and brain targeting via lactoferrin conjugation in treatment of glioblastoma
The objective of the work was to engineer lactoferrin conjugated temozolomide and resveratrol co-loaded NLC for the treatment of glioblastoma using intranasal delivery for brain targeting. Synergistic activity of temozolomide and resveratrol was determined using combination index method and 1:1 ratio was selected. QbD approach was used to formulate and optimize NLC, with minimum particle size, maximum transmittance and entrapment efficiency using Central Composite Rotable Design (CCRD) method. The optimized LTR-NLC had desired average particle size (209.3 nm), narrow PDI along, high percentage transmittance (>95%) and b...
Source: European Journal of Pharmaceutics and Biopharmaceutics - August 30, 2023 Category: Drugs & Pharmacology Authors: Saurabh Mittal Sadia Shah Harlokesh Narayan Yadav Javed Ali Madan Mohan Gupta Sanjula Baboota Source Type: research
Local administration of shikonin improved the overall survival in orthotopic murine glioblastoma models with temozolomide resistance
CONCLUSIONS: The direct intracranial infusion of shikonin has potential as a local therapy for patients with glioblastoma.PMID:37557011 | DOI:10.1016/j.biopha.2023.115296
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - August 9, 2023 Category: Drugs & Pharmacology Authors: Ryosuke Maeoka Yukiteru Ouji Tsutomu Nakazawa Ryosuke Matsuda Takayuki Morimoto Shohei Yokoyama Shuichi Yamada Fumihiko Nishimura Ichiro Nakagawa Young-Soo Park Masahide Yoshikawa Hiroyuki Nakase Source Type: research
Epigenetic regulation of temozolomide resistance in human cancers with an emphasis on brain tumors: Function of non-coding RNAs
Biomed Pharmacother. 2023 Jul 25;165:115187. doi: 10.1016/j.biopha.2023.115187. Online ahead of print.ABSTRACTBrain tumors, which are highly malignant, pose a significant threat to health and often result in substantial rates of mortality and morbidity worldwide. The brain cancer therapy has been challenging due to obstacles such as the BBB, which hinders effective delivery of therapeutic agents. Additionally, the emergence of drug resistance further complicates the management of brain tumors. TMZ is utilized in brain cancer removal, but resistance is a drawback. ncRNAs are implicated in various diseases, and their involve...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 27, 2023 Category: Drugs & Pharmacology Authors: Aryan Rezaee Pooya M Tehrany Farimah Jafari Tirabadi Negin Sanadgol Asal Sadat Karimi Atra Ajdari Sepideh Eydivandi Sara Etemad Romina Rajabi Parham Rahmanian Ramin Khorrami Noushin Nabavi Amir Reza Aref Xiaoping Fan Rongjun Zou Mohsen Rashidi Mohammad Ar Source Type: research
Strategies increasing the effectiveness of temozolomide at various levels of anti-GBL therapy
Biomed Pharmacother. 2023 Jul 15;165:115174. doi: 10.1016/j.biopha.2023.115174. Online ahead of print.ABSTRACTGlioblastoma (GBL) is the most common (60-70% of primary brain tumours) and the most malignant of the glial tumours. Although current therapies remain palliative, they have been proven to prolong overall survival. Within an optimal treatment regimen (incl. surgical resection, radiation therapy, and chemotherapy) temozolomide as the current anti-GBL first-line chemotherapeutic has increased the median overall survival to 14-15 months, and the percentage of patients alive at two years has been reported to rise from 1...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 17, 2023 Category: Drugs & Pharmacology Authors: Aleksandra Krajcer Ewelina Grzywna Joanna Lewandowska- Łańcucka Source Type: research
New therapy for pancreatic cancer based on extracellular vesicles
Biomed Pharmacother. 2023 Apr 4;162:114657. doi: 10.1016/j.biopha.2023.114657. Online ahead of print.ABSTRACTPancreatic Ductal Adenocarcinoma (PDAC), is the most common aggressive cancer of the pancreas. The standard care of PDAC includes tumor resection and chemotherapy, but the lack of early diagnosis and the limited response to the treatment worsens the patient's condition. In order to improve the efficiency of chemotherapy, we look for more efficient systems of drug delivery. We isolated and fully characterized small Extracellular Vesicles (EVs) from the RWP-1 cell line. Our study indicates that the direct incubation m...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 6, 2023 Category: Drugs & Pharmacology Authors: Salom é Araujo-Abad Antonio Manresa-Manresa Enrique Rodr íguez-Cañas Mar ía Fuentes-Baile Pilar Garc ía-Morales Ricardo Mallavia Miguel Saceda Camino de Juan Romero Source Type: research
Sitagliptin inhibits the survival, stemness and autophagy of glioma cells, and enhances temozolomide cytotoxicity
Biomed Pharmacother. 2023 Mar 24;162:114555. doi: 10.1016/j.biopha.2023.114555. Online ahead of print.ABSTRACTThe standard regimen treatment has improved GBM outcomes, but the survival rate of patients is still unsatisfactory. Temozolomide (TMZ) resistance is one of main reasons limiting the therapeutic efficacy of GBM. However, there are currently no TMZ-sensitizing drugs available in the clinic. Here we aimed to study whether the antidiabetic drug Sitagliptin can inhibit the survival, stemness and autophagy of GBM cells, and thus enhance TMZ cytotoxicity. We used CCK-8, EdU, colony formation, TUNEL and flow cytometry ass...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - March 26, 2023 Category: Drugs & Pharmacology Authors: Fangting You Cheng Li Shicheng Zhang Qiaoshan Zhang Zhiyuan Hu Yuhui Wang Tong Zhang Qingming Meng Rutong Yu Shangfeng Gao Source Type: research
Exploring temozolomide encapsulated PEGylated Liposomes and Lyotropic liquid crystals for effective treatment of glioblastoma: in-vitro, cell line, and pharmacokinetic studies
Eur J Pharm Biopharm. 2023 Mar 14:S0939-6411(23)00064-4. doi: 10.1016/j.ejpb.2023.03.004. Online ahead of print.ABSTRACTTemozolomide (TMZ) is one of the best choices for treating glioblastoma. However, due to the short plasma half-life, only 20-30 % brain bioavailability can be achieved using traditional formulations. In the present study, PEGylated liposomes and lyotropic liquid crystals (LLCs) were developed and investigated to prolong the plasma circulation time of TMZ. Industrially feasible membrane extrusion and modified hot melt emulsification techniques were utilized during the formulation. Liposomes and LLCs in the...
Source: European Journal of Pharmaceutics and Biopharmaceutics - March 16, 2023 Category: Drugs & Pharmacology Authors: Tejashree Waghule K Laxmi Swetha Aniruddha Roy Ranendra Narayan Saha Gautam Singhvi Source Type: research
